nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—Gastrointestinal perforation—Erlotinib—pancreatic cancer	0.0568	0.0984	CcSEcCtD
Methylnaltrexone—Gastrointestinal perforation—Sunitinib—pancreatic cancer	0.0491	0.0852	CcSEcCtD
Methylnaltrexone—Gastrointestinal perforation—Docetaxel—pancreatic cancer	0.028	0.0485	CcSEcCtD
Methylnaltrexone—Redness—Tamoxifen—pancreatic cancer	0.0222	0.0384	CcSEcCtD
Methylnaltrexone—CYP2D6—Tamoxifen—pancreatic cancer	0.0172	0.44	CbGbCtD
Methylnaltrexone—CYP2D6—Erlotinib—pancreatic cancer	0.0146	0.374	CbGbCtD
Methylnaltrexone—Stinging—Fluorouracil—pancreatic cancer	0.0125	0.0216	CcSEcCtD
Methylnaltrexone—Redness—Docetaxel—pancreatic cancer	0.0108	0.0187	CcSEcCtD
Methylnaltrexone—Injection site reaction—Gemcitabine—pancreatic cancer	0.0102	0.0177	CcSEcCtD
Methylnaltrexone—Redness—Epirubicin—pancreatic cancer	0.0073	0.0126	CcSEcCtD
Methylnaltrexone—Injection site reaction—Docetaxel—pancreatic cancer	0.00726	0.0126	CcSEcCtD
Methylnaltrexone—CYP2D6—Doxorubicin—pancreatic cancer	0.00723	0.185	CbGbCtD
Methylnaltrexone—Redness—Doxorubicin—pancreatic cancer	0.00675	0.0117	CcSEcCtD
Methylnaltrexone—Erythema—Tamoxifen—pancreatic cancer	0.00655	0.0113	CcSEcCtD
Methylnaltrexone—Erythema—Erlotinib—pancreatic cancer	0.00648	0.0112	CcSEcCtD
Methylnaltrexone—Flatulence—Erlotinib—pancreatic cancer	0.00638	0.0111	CcSEcCtD
Methylnaltrexone—Stinging—Epirubicin—pancreatic cancer	0.00608	0.0105	CcSEcCtD
Methylnaltrexone—Stinging—Doxorubicin—pancreatic cancer	0.00563	0.00975	CcSEcCtD
Methylnaltrexone—Erythema—Sunitinib—pancreatic cancer	0.00561	0.00972	CcSEcCtD
Methylnaltrexone—Flatulence—Sunitinib—pancreatic cancer	0.00552	0.00957	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.00548	0.00949	CcSEcCtD
Methylnaltrexone—Oedema—Tamoxifen—pancreatic cancer	0.00534	0.00926	CcSEcCtD
Methylnaltrexone—Oedema—Erlotinib—pancreatic cancer	0.00529	0.00916	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Erlotinib—pancreatic cancer	0.00518	0.00898	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Tamoxifen—pancreatic cancer	0.00516	0.00895	CcSEcCtD
Methylnaltrexone—Skin disorder—Erlotinib—pancreatic cancer	0.00513	0.0089	CcSEcCtD
Methylnaltrexone—Injection site reaction—Epirubicin—pancreatic cancer	0.0049	0.00849	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.00474	0.00821	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00461	0.00799	CcSEcCtD
Methylnaltrexone—Oedema—Sunitinib—pancreatic cancer	0.00458	0.00793	CcSEcCtD
Methylnaltrexone—Pain—Tamoxifen—pancreatic cancer	0.00457	0.00792	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.00456	0.00791	CcSEcCtD
Methylnaltrexone—Flatulence—Irinotecan—pancreatic cancer	0.00455	0.00789	CcSEcCtD
Methylnaltrexone—Injection site reaction—Doxorubicin—pancreatic cancer	0.00453	0.00785	CcSEcCtD
Methylnaltrexone—Pain—Erlotinib—pancreatic cancer	0.00452	0.00783	CcSEcCtD
Methylnaltrexone—Erythema—Gemcitabine—pancreatic cancer	0.0045	0.0078	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Sunitinib—pancreatic cancer	0.00449	0.00778	CcSEcCtD
Methylnaltrexone—Skin disorder—Sunitinib—pancreatic cancer	0.00444	0.0077	CcSEcCtD
Methylnaltrexone—Erythema—Fluorouracil—pancreatic cancer	0.00442	0.00767	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.00437	0.00757	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00432	0.00749	CcSEcCtD
Methylnaltrexone—Abdominal pain—Tamoxifen—pancreatic cancer	0.00422	0.00732	CcSEcCtD
Methylnaltrexone—Abdominal pain—Erlotinib—pancreatic cancer	0.00418	0.00724	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00395	0.00685	CcSEcCtD
Methylnaltrexone—Pain—Sunitinib—pancreatic cancer	0.00391	0.00678	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.0038	0.00659	CcSEcCtD
Methylnaltrexone—Oedema—Irinotecan—pancreatic cancer	0.00377	0.00653	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00374	0.00648	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Irinotecan—pancreatic cancer	0.0037	0.00641	CcSEcCtD
Methylnaltrexone—Oedema—Gemcitabine—pancreatic cancer	0.00367	0.00636	CcSEcCtD
Methylnaltrexone—Diarrhoea—Tamoxifen—pancreatic cancer	0.00366	0.00633	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Irinotecan—pancreatic cancer	0.00364	0.00631	CcSEcCtD
Methylnaltrexone—Abdominal pain—Sunitinib—pancreatic cancer	0.00362	0.00627	CcSEcCtD
Methylnaltrexone—Diarrhoea—Erlotinib—pancreatic cancer	0.00362	0.00627	CcSEcCtD
Methylnaltrexone—Oedema—Fluorouracil—pancreatic cancer	0.00361	0.00626	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Gemcitabine—pancreatic cancer	0.0036	0.00624	CcSEcCtD
Methylnaltrexone—Skin disorder—Gemcitabine—pancreatic cancer	0.00357	0.00618	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.00355	0.00615	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00354	0.00613	CcSEcCtD
Methylnaltrexone—Dizziness—Tamoxifen—pancreatic cancer	0.00353	0.00612	CcSEcCtD
Methylnaltrexone—Dizziness—Erlotinib—pancreatic cancer	0.0035	0.00606	CcSEcCtD
Methylnaltrexone—Vomiting—Tamoxifen—pancreatic cancer	0.0034	0.00589	CcSEcCtD
Methylnaltrexone—Vomiting—Erlotinib—pancreatic cancer	0.00336	0.00582	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00325	0.00564	CcSEcCtD
Methylnaltrexone—Pain—Irinotecan—pancreatic cancer	0.00322	0.00559	CcSEcCtD
Methylnaltrexone—Erythema—Docetaxel—pancreatic cancer	0.00319	0.00553	CcSEcCtD
Methylnaltrexone—Nausea—Tamoxifen—pancreatic cancer	0.00317	0.0055	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00317	0.00549	CcSEcCtD
Methylnaltrexone—Pain—Gemcitabine—pancreatic cancer	0.00314	0.00544	CcSEcCtD
Methylnaltrexone—Nausea—Erlotinib—pancreatic cancer	0.00314	0.00544	CcSEcCtD
Methylnaltrexone—Diarrhoea—Sunitinib—pancreatic cancer	0.00313	0.00543	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00312	0.0054	CcSEcCtD
Methylnaltrexone—Pain—Fluorouracil—pancreatic cancer	0.00309	0.00535	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00308	0.00534	CcSEcCtD
Methylnaltrexone—Dizziness—Sunitinib—pancreatic cancer	0.00303	0.00524	CcSEcCtD
Methylnaltrexone—Abdominal pain—Irinotecan—pancreatic cancer	0.00298	0.00516	CcSEcCtD
Methylnaltrexone—Vomiting—Sunitinib—pancreatic cancer	0.00291	0.00504	CcSEcCtD
Methylnaltrexone—Nausea—Sunitinib—pancreatic cancer	0.00272	0.00471	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.0027	0.00468	CcSEcCtD
Methylnaltrexone—Oedema—Docetaxel—pancreatic cancer	0.00261	0.00452	CcSEcCtD
Methylnaltrexone—Diarrhoea—Irinotecan—pancreatic cancer	0.00258	0.00447	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Docetaxel—pancreatic cancer	0.00255	0.00443	CcSEcCtD
Methylnaltrexone—Skin disorder—Docetaxel—pancreatic cancer	0.00253	0.00439	CcSEcCtD
Methylnaltrexone—Diarrhoea—Gemcitabine—pancreatic cancer	0.00251	0.00435	CcSEcCtD
Methylnaltrexone—Dizziness—Irinotecan—pancreatic cancer	0.00249	0.00432	CcSEcCtD
Methylnaltrexone—Diarrhoea—Fluorouracil—pancreatic cancer	0.00247	0.00428	CcSEcCtD
Methylnaltrexone—Vomiting—Irinotecan—pancreatic cancer	0.0024	0.00415	CcSEcCtD
Methylnaltrexone—Dizziness—Fluorouracil—pancreatic cancer	0.00239	0.00414	CcSEcCtD
Methylnaltrexone—Vomiting—Gemcitabine—pancreatic cancer	0.00233	0.00405	CcSEcCtD
Methylnaltrexone—Vomiting—Fluorouracil—pancreatic cancer	0.0023	0.00398	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00225	0.0039	CcSEcCtD
Methylnaltrexone—Nausea—Irinotecan—pancreatic cancer	0.00224	0.00388	CcSEcCtD
Methylnaltrexone—Pain—Docetaxel—pancreatic cancer	0.00223	0.00386	CcSEcCtD
Methylnaltrexone—Nausea—Gemcitabine—pancreatic cancer	0.00218	0.00378	CcSEcCtD
Methylnaltrexone—Erythema—Epirubicin—pancreatic cancer	0.00215	0.00373	CcSEcCtD
Methylnaltrexone—Nausea—Fluorouracil—pancreatic cancer	0.00214	0.00372	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00213	0.00369	CcSEcCtD
Methylnaltrexone—Flatulence—Epirubicin—pancreatic cancer	0.00212	0.00368	CcSEcCtD
Methylnaltrexone—Abdominal pain—Docetaxel—pancreatic cancer	0.00206	0.00357	CcSEcCtD
Methylnaltrexone—Erythema—Doxorubicin—pancreatic cancer	0.00199	0.00345	CcSEcCtD
Methylnaltrexone—Flatulence—Doxorubicin—pancreatic cancer	0.00196	0.0034	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.00182	0.00316	CcSEcCtD
Methylnaltrexone—Diarrhoea—Docetaxel—pancreatic cancer	0.00178	0.00309	CcSEcCtD
Methylnaltrexone—Oedema—Epirubicin—pancreatic cancer	0.00176	0.00305	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Epirubicin—pancreatic cancer	0.00172	0.00299	CcSEcCtD
Methylnaltrexone—Dizziness—Docetaxel—pancreatic cancer	0.00172	0.00299	CcSEcCtD
Methylnaltrexone—Skin disorder—Epirubicin—pancreatic cancer	0.00171	0.00296	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Epirubicin—pancreatic cancer	0.0017	0.00294	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.00168	0.00292	CcSEcCtD
Methylnaltrexone—Vomiting—Docetaxel—pancreatic cancer	0.00166	0.00287	CcSEcCtD
Methylnaltrexone—Oedema—Doxorubicin—pancreatic cancer	0.00163	0.00282	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Doxorubicin—pancreatic cancer	0.00159	0.00276	CcSEcCtD
Methylnaltrexone—Skin disorder—Doxorubicin—pancreatic cancer	0.00158	0.00274	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.00157	0.00272	CcSEcCtD
Methylnaltrexone—Nausea—Docetaxel—pancreatic cancer	0.00155	0.00268	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.00152	0.00263	CcSEcCtD
Methylnaltrexone—Pain—Epirubicin—pancreatic cancer	0.0015	0.0026	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.00144	0.00249	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.0014	0.00243	CcSEcCtD
Methylnaltrexone—Pain—Doxorubicin—pancreatic cancer	0.00139	0.00241	CcSEcCtD
Methylnaltrexone—Abdominal pain—Epirubicin—pancreatic cancer	0.00139	0.00241	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.00133	0.0023	CcSEcCtD
Methylnaltrexone—Abdominal pain—Doxorubicin—pancreatic cancer	0.00129	0.00223	CcSEcCtD
Methylnaltrexone—Diarrhoea—Epirubicin—pancreatic cancer	0.0012	0.00208	CcSEcCtD
Methylnaltrexone—Dizziness—Epirubicin—pancreatic cancer	0.00116	0.00201	CcSEcCtD
Methylnaltrexone—Vomiting—Epirubicin—pancreatic cancer	0.00112	0.00194	CcSEcCtD
Methylnaltrexone—Diarrhoea—Doxorubicin—pancreatic cancer	0.00111	0.00193	CcSEcCtD
Methylnaltrexone—Dizziness—Doxorubicin—pancreatic cancer	0.00108	0.00186	CcSEcCtD
Methylnaltrexone—Nausea—Epirubicin—pancreatic cancer	0.00104	0.00181	CcSEcCtD
Methylnaltrexone—Vomiting—Doxorubicin—pancreatic cancer	0.00103	0.00179	CcSEcCtD
Methylnaltrexone—Nausea—Doxorubicin—pancreatic cancer	0.000966	0.00167	CcSEcCtD
Methylnaltrexone—OPRK1—GPCR downstream signaling—SCT—pancreatic cancer	0.000701	0.00183	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CNR1—pancreatic cancer	0.000699	0.00182	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PPY—pancreatic cancer	0.000696	0.00181	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CXCL8—pancreatic cancer	0.000684	0.00178	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—SSTR2—pancreatic cancer	0.000683	0.00178	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—GCG—pancreatic cancer	0.000675	0.00176	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GAST—pancreatic cancer	0.000671	0.00175	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCK—pancreatic cancer	0.000669	0.00174	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCKBR—pancreatic cancer	0.00066	0.00172	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CNR2—pancreatic cancer	0.000652	0.0017	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000652	0.0017	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—AGTR1—pancreatic cancer	0.000644	0.00168	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000641	0.00167	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—SCT—pancreatic cancer	0.000636	0.00166	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GAST—pancreatic cancer	0.000625	0.00163	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—HRAS—pancreatic cancer	0.000617	0.00161	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRLHR—pancreatic cancer	0.000609	0.00159	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCK—pancreatic cancer	0.000607	0.00158	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—SCT—pancreatic cancer	0.000592	0.00154	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CNR2—pancreatic cancer	0.000592	0.00154	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GLP1R—pancreatic cancer	0.000592	0.00154	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCKAR—pancreatic cancer	0.000582	0.00152	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CXCL8—pancreatic cancer	0.000578	0.00151	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—IAPP—pancreatic cancer	0.000577	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CXCL8—pancreatic cancer	0.000577	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ZNRF3—pancreatic cancer	0.000572	0.00149	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ACVR1B—pancreatic cancer	0.000572	0.00149	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GAST—pancreatic cancer	0.000567	0.00148	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCK—pancreatic cancer	0.000565	0.00147	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000554	0.00144	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CNR2—pancreatic cancer	0.000551	0.00143	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000551	0.00143	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—AKT1—pancreatic cancer	0.000545	0.00142	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000542	0.00141	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—SCT—pancreatic cancer	0.000538	0.0014	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—SHH—pancreatic cancer	0.000531	0.00138	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IAPP—pancreatic cancer	0.000524	0.00137	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—DTX1—pancreatic cancer	0.000517	0.00135	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SSTR3—pancreatic cancer	0.000517	0.00135	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRLHR—pancreatic cancer	0.000514	0.00134	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCK—pancreatic cancer	0.000513	0.00134	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—SST—pancreatic cancer	0.000507	0.00132	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PTCH1—pancreatic cancer	0.000503	0.00131	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PTHLH—pancreatic cancer	0.000503	0.00131	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CNR2—pancreatic cancer	0.0005	0.0013	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GLP1R—pancreatic cancer	0.0005	0.0013	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SSTR1—pancreatic cancer	0.000496	0.00129	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCKAR—pancreatic cancer	0.000492	0.00128	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—IAPP—pancreatic cancer	0.000488	0.00127	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CXCL8—pancreatic cancer	0.000488	0.00127	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PPY—pancreatic cancer	0.000486	0.00127	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ACVR1B—pancreatic cancer	0.000484	0.00126	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ZNRF3—pancreatic cancer	0.000484	0.00126	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SSTR2—pancreatic cancer	0.000478	0.00124	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000468	0.00122	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CNR1—pancreatic cancer	0.000468	0.00122	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCKBR—pancreatic cancer	0.000461	0.0012	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—SST—pancreatic cancer	0.00046	0.0012	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000459	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GCG—pancreatic cancer	0.000452	0.00118	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—SHH—pancreatic cancer	0.000448	0.00117	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IAPP—pancreatic cancer	0.000443	0.00115	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SSTR3—pancreatic cancer	0.000437	0.00114	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DTX1—pancreatic cancer	0.000437	0.00114	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—DTX4—pancreatic cancer	0.000434	0.00113	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GLI1—pancreatic cancer	0.000434	0.00113	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000431	0.00112	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—SST—pancreatic cancer	0.000428	0.00112	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PTHLH—pancreatic cancer	0.000425	0.00111	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PTCH1—pancreatic cancer	0.000425	0.00111	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CNR1—pancreatic cancer	0.000425	0.00111	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NRP1—pancreatic cancer	0.000422	0.0011	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000422	0.0011	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SSTR1—pancreatic cancer	0.000419	0.00109	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PPY—pancreatic cancer	0.000411	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GCG—pancreatic cancer	0.00041	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HEY2—pancreatic cancer	0.000406	0.00106	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SSTR2—pancreatic cancer	0.000404	0.00105	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GAST—pancreatic cancer	0.000397	0.00103	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CNR1—pancreatic cancer	0.000395	0.00103	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AGTR1—pancreatic cancer	0.000391	0.00102	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCKBR—pancreatic cancer	0.00039	0.00102	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—SST—pancreatic cancer	0.000389	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000388	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GCG—pancreatic cancer	0.000382	0.000994	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SCT—pancreatic cancer	0.000376	0.000979	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HEY1—pancreatic cancer	0.000376	0.000979	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GLI1—pancreatic cancer	0.000366	0.000955	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DTX4—pancreatic cancer	0.000366	0.000955	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000364	0.000948	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CNR1—pancreatic cancer	0.000359	0.000935	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCK—pancreatic cancer	0.000359	0.000934	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NRP1—pancreatic cancer	0.000356	0.000929	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000356	0.000929	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CNR2—pancreatic cancer	0.00035	0.00091	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GLP1R—pancreatic cancer	0.00035	0.00091	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCL8—pancreatic cancer	0.000349	0.00091	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GCG—pancreatic cancer	0.000347	0.000903	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCKAR—pancreatic cancer	0.000344	0.000896	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HEY2—pancreatic cancer	0.000343	0.000894	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GAST—pancreatic cancer	0.000335	0.000873	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JAG2—pancreatic cancer	0.000333	0.000869	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AGTR1—pancreatic cancer	0.000331	0.000861	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MEN1—pancreatic cancer	0.000329	0.000856	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SCT—pancreatic cancer	0.000318	0.000828	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HEY1—pancreatic cancer	0.000318	0.000828	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SHH—pancreatic cancer	0.000313	0.000817	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH4—pancreatic cancer	0.000312	0.000811	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IAPP—pancreatic cancer	0.00031	0.000806	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCK—pancreatic cancer	0.000303	0.00079	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTHLH—pancreatic cancer	0.000297	0.000774	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTCH1—pancreatic cancer	0.000297	0.000774	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GLP1R—pancreatic cancer	0.000295	0.000769	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CNR2—pancreatic cancer	0.000295	0.000769	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCL8—pancreatic cancer	0.000295	0.000769	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCKAR—pancreatic cancer	0.000291	0.000757	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JAG2—pancreatic cancer	0.000282	0.000734	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MEN1—pancreatic cancer	0.000278	0.000723	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SST—pancreatic cancer	0.000272	0.000708	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000268	0.000698	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JAG1—pancreatic cancer	0.000266	0.000693	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SHH—pancreatic cancer	0.000265	0.00069	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH3—pancreatic cancer	0.000265	0.00069	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH4—pancreatic cancer	0.000263	0.000686	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IAPP—pancreatic cancer	0.000262	0.000682	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PRSS1—pancreatic cancer	0.000256	0.000666	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTCH1—pancreatic cancer	0.000251	0.000654	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTHLH—pancreatic cancer	0.000251	0.000654	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CNR1—pancreatic cancer	0.000251	0.000653	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000243	0.000634	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GCG—pancreatic cancer	0.000242	0.000631	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000236	0.000614	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AGTR1—pancreatic cancer	0.000231	0.000602	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SST—pancreatic cancer	0.00023	0.000598	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STK11—pancreatic cancer	0.000228	0.000593	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000227	0.00059	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JAG1—pancreatic cancer	0.000225	0.000586	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH3—pancreatic cancer	0.000224	0.000583	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ARG2—pancreatic cancer	0.000222	0.000577	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000214	0.000557	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CNR1—pancreatic cancer	0.000212	0.000552	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000206	0.000536	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000205	0.000535	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GCG—pancreatic cancer	0.000205	0.000533	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SMAD4—pancreatic cancer	0.000199	0.00052	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000199	0.000519	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000197	0.000514	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AGTR1—pancreatic cancer	0.000195	0.000509	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HES1—pancreatic cancer	0.000195	0.000507	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TYMP—pancreatic cancer	0.000194	0.000505	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STK11—pancreatic cancer	0.000193	0.000501	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000187	0.000486	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000181	0.000471	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL8—pancreatic cancer	0.000179	0.000467	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000174	0.000452	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TERT—pancreatic cancer	0.000171	0.000445	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SMAD4—pancreatic cancer	0.000169	0.000439	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000167	0.000435	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HES1—pancreatic cancer	0.000165	0.000429	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HIF1A—pancreatic cancer	0.000163	0.000425	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TSC2—pancreatic cancer	0.000163	0.000424	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOE—pancreatic cancer	0.000159	0.000415	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000158	0.000411	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GLP1R—pancreatic cancer	0.000156	0.000407	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KDR—pancreatic cancer	0.000156	0.000407	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—DPYD—pancreatic cancer	0.000154	0.0004	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL8—pancreatic cancer	0.000151	0.000395	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NFKBIA—pancreatic cancer	0.000148	0.000387	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH1—pancreatic cancer	0.000147	0.000383	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	0.000146	0.00038	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TERT—pancreatic cancer	0.000144	0.000376	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CG—pancreatic cancer	0.000144	0.000375	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—NRAS—pancreatic cancer	0.000144	0.000375	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGF—pancreatic cancer	0.000142	0.00037	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HIF1A—pancreatic cancer	0.000138	0.000359	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TSC2—pancreatic cancer	0.000138	0.000358	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOE—pancreatic cancer	0.000135	0.000351	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KDR—pancreatic cancer	0.000132	0.000344	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EGFR—pancreatic cancer	0.000131	0.000341	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CD—pancreatic cancer	0.000126	0.000329	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NFKBIA—pancreatic cancer	0.000125	0.000327	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CA—pancreatic cancer	0.000125	0.000326	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH1—pancreatic cancer	0.000124	0.000324	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—KRAS—pancreatic cancer	0.000124	0.000322	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CG—pancreatic cancer	0.000122	0.000317	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—NRAS—pancreatic cancer	0.000122	0.000317	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGF—pancreatic cancer	0.00012	0.000313	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CA—pancreatic cancer	0.000114	0.000296	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CD44—pancreatic cancer	0.000113	0.000294	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EGFR—pancreatic cancer	0.000111	0.000288	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CB—pancreatic cancer	0.00011	0.000287	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GCG—pancreatic cancer	0.000108	0.000282	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CD—pancreatic cancer	0.000107	0.000278	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL8—pancreatic cancer	0.000106	0.000276	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	0.000106	0.000276	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HRAS—pancreatic cancer	0.000105	0.000274	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—KRAS—pancreatic cancer	0.000105	0.000272	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT1—pancreatic cancer	0.000102	0.000266	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—STK11—pancreatic cancer	0.000102	0.000265	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP3—pancreatic cancer	0.000101	0.000264	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCND1—pancreatic cancer	9.87e-05	0.000257	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CTNNB1—pancreatic cancer	9.77e-05	0.000254	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	9.61e-05	0.00025	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—pancreatic cancer	9.58e-05	0.000249	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTEN—pancreatic cancer	9.52e-05	0.000248	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CB—pancreatic cancer	9.31e-05	0.000243	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT1—pancreatic cancer	9.29e-05	0.000242	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL8—pancreatic cancer	8.95e-05	0.000233	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HRAS—pancreatic cancer	8.89e-05	0.000232	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SRC—pancreatic cancer	8.83e-05	0.00023	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TYMS—pancreatic cancer	8.75e-05	0.000228	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT1—pancreatic cancer	8.65e-05	0.000225	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFA—pancreatic cancer	8.6e-05	0.000224	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP3—pancreatic cancer	8.57e-05	0.000223	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT3—pancreatic cancer	8.52e-05	0.000222	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NRAS—pancreatic cancer	8.5e-05	0.000221	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCND1—pancreatic cancer	8.34e-05	0.000217	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CTNNB1—pancreatic cancer	8.26e-05	0.000215	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—pancreatic cancer	8.09e-05	0.000211	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTEN—pancreatic cancer	8.05e-05	0.00021	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MYC—pancreatic cancer	7.91e-05	0.000206	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFB1—pancreatic cancer	7.89e-05	0.000206	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT1—pancreatic cancer	7.85e-05	0.000205	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGFR—pancreatic cancer	7.74e-05	0.000202	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SRC—pancreatic cancer	7.46e-05	0.000194	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KRAS—pancreatic cancer	7.31e-05	0.00019	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFA—pancreatic cancer	7.27e-05	0.000189	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT3—pancreatic cancer	7.2e-05	0.000187	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NRAS—pancreatic cancer	7.18e-05	0.000187	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOE—pancreatic cancer	7.12e-05	0.000185	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CA—pancreatic cancer	6.72e-05	0.000175	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MYC—pancreatic cancer	6.69e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFB1—pancreatic cancer	6.67e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGFR—pancreatic cancer	6.54e-05	0.00017	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TP53—pancreatic cancer	6.5e-05	0.000169	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	6.43e-05	0.000167	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HRAS—pancreatic cancer	6.21e-05	0.000162	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARG—pancreatic cancer	6.2e-05	0.000162	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KRAS—pancreatic cancer	6.18e-05	0.000161	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CA—pancreatic cancer	5.68e-05	0.000148	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	5.65e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TP53—pancreatic cancer	5.49e-05	0.000143	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT1—pancreatic cancer	5.49e-05	0.000143	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HRAS—pancreatic cancer	5.25e-05	0.000137	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	4.92e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—pancreatic cancer	4.88e-05	0.000127	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT1—pancreatic cancer	4.64e-05	0.000121	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTEN—pancreatic cancer	4.25e-05	0.000111	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	3e-05	7.82e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.45e-05	6.39e-05	CbGpPWpGaD
